Lantheus Holdings, Inc. (LNTH): Total Assets
$2.23B
As of 2025-12-31
$2.41B
As of 2026-06-30
+19.0%
3-year compound annual growth
+20.7%
5-year compound annual growth
+24.8%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.23B | +12.5% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $1.98B | +19.9% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $1.65B | +25.0% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $1.32B | +53.0% | 2024-02-22, Balance as of period end |
| 2021-12-31 | $863.78M | -0.7% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $869.82M | +114.3% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $405.92M | -7.7% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $439.83M | +14.6% | 2020-02-25, Balance as of period end |
| 2017-12-31 | $383.86M | +50.0% | 2019-02-20, Balance as of period end |
| 2016-12-31 | $255.90M | +5.6% | 2018-02-26, Balance as of period end |
| 2015-12-31 | $242.38M | -0.3% | 2017-02-23, Balance as of period end |
| 2014-12-31 | $243.15M | n/a | 2016-03-02, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | 2025-12-31 | $2.23B | +12.5% |
| QuidelOrtho Corp (QDEL) | 2025-12-28 | $5.77B | -10.2% |
| Neogen Corp (NEOG) | 2026-05-31 | $3.35B | -2.8% |
| Myriad Genetics Inc (MYGN) | 2025-12-31 | $706.60M | -31.2% |
| Idexx Laboratories Inc (IDXX) | 2025-12-31 | $3.35B | +1.7% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $842.13M | -29.3% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $103.58M | -12.8% |
| Immucell Corp (ICCC) | 2025-12-31 | $42.53M | -5.7% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $5.46M | -0.6% |
Compare LNTH, QDEL, NEOG, MYGN side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗